Increased Levels of CD107a and Intracellular Cytokines in IL-2 Stimulated PBMCs from Endometriosis Patients.

IF 2.6 Q3 IMMUNOLOGY International Journal of Inflammation Pub Date : 2021-09-27 DOI:10.1155/2021/5760959
R Muharam, Ririn Rahmala Febri, Kevin Ardito Prabowo, Arleni Bustami, Indra G Mansur
{"title":"Increased Levels of CD107a and Intracellular Cytokines in IL-2 Stimulated PBMCs from Endometriosis Patients.","authors":"R Muharam,&nbsp;Ririn Rahmala Febri,&nbsp;Kevin Ardito Prabowo,&nbsp;Arleni Bustami,&nbsp;Indra G Mansur","doi":"10.1155/2021/5760959","DOIUrl":null,"url":null,"abstract":"<p><p>It has been postulated that the immune system is impaired in individuals with endometriosis, with attention directed to natural killer (NK) cells. Specifically, it has been hypothesized that altered numbers of peripheral NK cells in blood are associated with the presence of endometriotic lesions. This study aimed to evaluate the level of the peripheral NK cell surface marker CD107a in endometriosis in the presence of IL-2 stimulation. Peripheral blood mononuclear cells (PBMCs) were obtained from 7 women with endometriosis and 7 women without endometriosis. The PBMCs were divided into two groups and either treated with recombinant IL-2 or left untreated. The cytotoxic activity of the PBMCs toward target cells (K562) was evaluated. Then, both groups were cocultured for 4 days. The expressions of CD107a, TNF-<i>α</i>, and IFN-<i>γ</i> were determined using flow cytometry analysis. There was no difference in the expression of CD107a prior to IL-2 stimulation in PBMCs from women with endometriosis compared to those from women without endometriosis. However, we observed upregulation of the expression of the surface marker CD107a after treatment in the endometriosis group. In addition, there was a significant difference in CD107a expression in the endometriosis group before versus after stimulation with IL-2 (<i>p</i> < 0.01). We also found no difference in the production of TNF-<i>α</i> and IFN-<i>γ</i> before versus after treatment with IL-2 in either groups. The levels of CD107a were significantly enhanced in peripheral blood taken from women with endometriosis after treatment with IL-2.</p>","PeriodicalId":14004,"journal":{"name":"International Journal of Inflammation","volume":"2021 ","pages":"5760959"},"PeriodicalIF":2.6000,"publicationDate":"2021-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490079/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Inflammation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2021/5760959","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

It has been postulated that the immune system is impaired in individuals with endometriosis, with attention directed to natural killer (NK) cells. Specifically, it has been hypothesized that altered numbers of peripheral NK cells in blood are associated with the presence of endometriotic lesions. This study aimed to evaluate the level of the peripheral NK cell surface marker CD107a in endometriosis in the presence of IL-2 stimulation. Peripheral blood mononuclear cells (PBMCs) were obtained from 7 women with endometriosis and 7 women without endometriosis. The PBMCs were divided into two groups and either treated with recombinant IL-2 or left untreated. The cytotoxic activity of the PBMCs toward target cells (K562) was evaluated. Then, both groups were cocultured for 4 days. The expressions of CD107a, TNF-α, and IFN-γ were determined using flow cytometry analysis. There was no difference in the expression of CD107a prior to IL-2 stimulation in PBMCs from women with endometriosis compared to those from women without endometriosis. However, we observed upregulation of the expression of the surface marker CD107a after treatment in the endometriosis group. In addition, there was a significant difference in CD107a expression in the endometriosis group before versus after stimulation with IL-2 (p < 0.01). We also found no difference in the production of TNF-α and IFN-γ before versus after treatment with IL-2 in either groups. The levels of CD107a were significantly enhanced in peripheral blood taken from women with endometriosis after treatment with IL-2.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
子宫内膜异位症患者IL-2刺激的PBMC中CD107a和细胞内细胞因子水平升高。
据推测,子宫内膜异位症患者的免疫系统受损,注意力集中在自然杀伤细胞上。具体而言,有人假设血液中外周NK细胞数量的改变与子宫内膜异位病变的存在有关。本研究旨在评估IL-2刺激下子宫内膜异位症患者外周NK细胞表面标志物CD107a的水平。外周血单核细胞(PBMC)取自7名子宫内膜异位症妇女和7名非子宫内膜异位病妇女。将PBMC分为两组,用重组IL-2处理或不处理。评估PBMC对靶细胞(K562)的细胞毒性活性。然后,两组共同培养4天。流式细胞术检测CD107a、TNF-α和IFN-γ的表达。在IL-2刺激之前,患有子宫内膜异位症的妇女的PBMC中CD107a的表达与没有子宫内膜异位病的妇女相比没有差异。然而,我们观察到子宫内膜异位症组治疗后表面标志物CD107a的表达上调。此外,子宫内膜异位症组在IL-2刺激前后CD107a的表达存在显著差异(p α和IFN-γ。子宫内膜异位症妇女经IL-2治疗后,外周血CD107a水平显著升高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.80
自引率
0.00%
发文量
16
审稿时长
16 weeks
期刊最新文献
Extended Inflammation Parameters (EIP) as Markers of Inflammation in Systemic Sclerosis. The Effect of Endotoxin-Induced Inflammation on the Activity of the Somatotropic Axis in Sheep. Characterization of a New Immunosuppressive and Antimicrobial Peptide, DRS-DA2, Isolated from the Mexican Frog, Pachymedusa dacnicolor. Association of Epstein-Barr Virus (EBV) and Human Endogenous Retroviruses (HERV) with Multiple Sclerosis in Northwest of Iran. Irisin and Cardiometabolic Disorders in Obesity: A Systematic Review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1